Antibiotic therapy for community-acquired pneumonia

Clinics in Chest Medicine

Volumn 20, Issue 3, 1999, Pages 589-598

  Mandell, L A ^a  

^a HENDERSON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; MACROLIDE; MONOBACTAM DERIVATIVE; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; TETRACYCLINE DERIVATIVE; TROVAFLOXACIN; UREIDOPENICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; COST BENEFIT ANALYSIS; DECISION MAKING; DIAGNOSTIC TEST; GRAM NEGATIVE BACTERIUM; HUMAN; INFECTION RISK; PNEUMONIA; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT PLANNING;

EID: 0032879744     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(05)70238-0     Document Type: Article

References (76)

1. M. Aubier R. Verster C. Regamey Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults Clin Inf Dis 26 1998 1312 1320
2. T.E. Auble D.M. Yealy M.J. Fine Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia Infect Dis Clin North Am 12 1998 741 759
3. P. Ball The Quinolones: History and Overview V.T. Andriole The Quinolones 1998 Academic Press San Diego 1 18
4. Ballow CH, Jones RN, Johnson D, et al: Regional trends in S. pneumoniae resistance: Results of a nationwide, multi-center trial In Abstracts of the 37th ICAAC, Toronto, Ontario, Canada, Sept. 28-Oct. 1, 1997.
5. J.G. Bartlett R.F. Breiman L.A. Mandell Community-acquired pneumonia in adults: Guidelines for management Clin Infect Dis 26 1998 811 838
6. J.G. Bartlett P. O'Keefe F. Talley Bacteriology of hospital-acquired pneumonia Arch Intern Med 146 1986 868 871
7. E. Berntsson T. Lagergard O. Strannegard Etiology of community-acquired pneumonia in outpatients Eur J Clin Microbiol 5 1996 446
8. C.R. Bodem L.M. Lampton D.P. Miller Endobrachial pH. Relevance to aminoglycoside activity in gram-negative bacillary pneumonia Am Rev Respir Dis 127 1983 39 41
9. A.C. Braude A. Hornstein M. Klein Pulmonary disposition of tobramycin Am Rev Respir Dis 127 1983 563 565
10. J.C. Butler J. Hofmann M.S. Cetron The continued emergency of drug-resistant Streptococcus pneumoniae in the United States: An update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System J Infect Dis 174 1996 986 993
11. CDC Defining the public health impact of drug-resistant S. pneumoniae : Report of a working group MMWR 45 RR-1 suppl 1996 1 20
12. R. Celis A. Torres J.M. Gatell Nosocomial pneumonia a multivariate analysis of risk and prognosis Chest 93 1988 318 324
13. C.W. Chow N. Senthiragah M. Rawje Interim report on drug utilization review of community-acquired and nosocomial pneumonia: Clinical, bacteriological and radiological spectrum Can J Infect Dis 5 suppl C 1994 20C
14. J.W. Chow M.J. Fine D.M. Shlaes Enterobacter bacteremia—Clinical features and emergence of antibiotic resistance during therapy Ann Intern Med 115 1991 585 590
15. W.A. Craig Penicillins S.L. Gorbach J.G. Bartlett N.R. Blacklow Infectious Diseases 1992 WB Saunders Philadelphia 160
16. W.A. Craig Antimicrobial resistance issues of the future Diagn Microbiol Infect Dis 25 1996 213 217
17. R.E. Dixon Economic costs of respiratory tract infections in the United States Am J Med 78 1985 45
18. G.V. Doern A. Brueggemann H.P. Holley Jr Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study Antimicrob Agents Chemother 40 1996 1208 1213
19. Erard PH, Moser F, Wenger A, et al: Prospective study on community-acquired pneumonia diagnosed and followed up by private practitioners. CHUV, Lausanne, Switzerland [abstract 56]. Abstracts of the 31st ICAAC, Chicago; Ill, October 1991.
20. G.D. Fang M. Fine J. Orloff New and emerging etiologies for community-acquired pneumonia with implications for therapy; a prospective multicenter study of 359 cases Medicine (Baltimore) 69 1990 307 316
21. T.M. File Jr J. Segreti L. Dunbar A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia Antimicrob Agents Chemother 41 1997 1965 1972
22. M.J. Fine M.A. Smith C.A. Carson Prognosis and outcomes of patients with community-acquired pneumonia JAMA 275 1996 134 141
23. I.R. Friedland K.P. Klugman Antibiotic-resistant pneumococcal disease in South African children Am J Dis Child 146 1992 920 923
24. I.R. Friedland G.H. McCracken Jr Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 331 1994 377 382
25. J.L. Gard R.B. Brown J.R. Garb Differences in etiology of pneumonias in nursing home and community patients JAMA 240 1978 2169
26. K. Gilbert M.J. Fine Assessing prognosis and predicting patient outcomes in community-acquired pneumonia Semin Respir Infect 9 1994 140 152
27. F.W. Goldstein Choice of an oral beta-lactam antibiotic for infections due to penicillin-resistant Streptococcus pneumoniae. Scand J Infect Dis 29 1997 255 257
28. D. Hansman M.M. Bullen A resistant pneumococcus [letter] Lancet 2 1967 264
29. C. Henquell C. Chanal D. Sirot Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli. Antimicrob Agents Chemother 39 1995 427 430
30. M.R. Jacobs H.J. Koornhof R.M. Robbins-Browne Emergence of multiple resistant pneumococci N Engl J Med 299 1978 735 740
31. G.A. Jacoby I. Carreras Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamses Antimicrob Agents Chemother 34 1990 858 862
32. Johnston NJ, deAzavedo JC, Kellner D, et al: Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in Streptococcus pneumoniae from across Canada [Abstract C-77a]. In Abstracts from the 37th ICAAC, Toronto, Ontario, Canada, Sept. 28-Oct. 1, 1997.
33. N. Joshi D.Q. Miller Doxycycline revisisted Arch Intern Med 157 1997 1421 1428
34. K.P. Klugman Pneumococcal resistance to antibiotics Clin Microbiol Rev 3 1990 171 196
35. K.P. Klugman The clinical relevance of in-vitro resistance to penicillin, ampicillin, amoxicillin and alternative agents, for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. J Antimicrob Chemother 38 suppl A 1996 S133 S140
36. K.P. Klugman C. Feldman The clinical relevance of antibiotic resistance in the management of pneumococcal pneumonia Infect Dis Clin Pract 7 1998 180 184
37. T. Kohler J.C. Pechere Bacterial resistance to quinolones V.T. Andriole The Quinolones 1998 Academic Press San Diego 117 142
38. D.B. Langille L. Yates T.J. Marrie Serological investigation of pneumonia as it presents to the physician's office Can J Infect Dis 4 1993 328
39. J. Lapointe J.H. Joncas Meningitis in a Canadian infant due to pneumococcus resistant to penicillin and chloramphenicol J Pediatr 103 1983 580 582
40. O. Leroy C. Santre C. Beuscart A 5-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an ICU Intensive Care Med 21 1995 24 31
41. M. Levy Community-acquired pneumonia: Importance of initial noninvasive bacteriologic and radiographic investigations Chest 92 1988 43 48
42. D.M. Livermore Beta-lactamses in laboratory and clinical resistance Clin Microbiol Rev 8 1995 557 584
43. D.E. Low Resistance issues and treatment implications: Pneumococcus, Staphylococcus aureus and gram-negative rods Infect Dis Clin North Am 12 1998 613 630
44. C.M. Luna P. Vujacich M.S. Niederman Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia Chest 111 1997 676 685
45. L.A. Mandell Antibiotics for pneumonia therapy Med Clin Norrth Am 78 1994 997 1014
46. L.A. Mandell M. Loeb Microbiology of hospital-acquired pneumonia Semin Respir Crit Care Med 18 1997 111 120
47. T.J. Marrie R.W. Peeling M.J. Fine Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course Am J Med 101 1996 508
48. B.J. Marston J.F. Plouffe T.M. File Incidence of community-acquired pneumonia requiring hospitalizations: Results of a population-based active surveillance study in Ohio Arch Intern Med 157 1997 1709 1718
49. L.K. McDougal R. Facklam M. Reeves Analysis of multiple antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States Antimicrob Agents Chemother 36 1992 2176 2184
50. R.C. Moellering Jr In vitro antibacterial activity of the aminoglycoside antibiotics Rev Infect Dis 5 suppl 2 1983 S212 S232
51. P. Moine J.-B. Vercken S. Chevret Severe community-acquired pneumonia: Etiology, epidemiology and prognostic factors Chest 105 1994 1487 1495
52. Moola S, Hagberg L, Churchyard A, et al: Comparison of grepafloxacin with clarithromycin in the treatment of community-acquired pneumonia (CAP) [Abstract #L-113] Abstracts of the 38th ICAAC, San Diego, September 24-27, 1998.
53. L.M. Mundy P.G. Auwaerter D. Oldach Community-acquired pneumonia: Impact of immune status Am J Respir Crit Care Med 152 1995 1309 1315
54. S. Naraqi G.P. Kirkpatrick S. Kabins Relapsing pneumococcal meningitis: Isolation of an organism with decreased susceptibility to penicillin G J Pediatr 85 1974 671 673
55. National Center for Health Statistics National hospital discharge survey: Annual summary 1990 Vital Health Stat 13 1992 1 225
56. National Committee for Clinical Laboratory Standards Performance Standards for Antimicrobial Susceptibility Testing. (NCCLS document M100-S5 supplement, vol 24, no 16) 1994 National Committee for Laboratory Standards Villanova, PA
57. J.M. Nava F. Bella J. Garau Predictive factors for invasive disease due to penicillin-resistant Staphylococcus pneumoniae. A population-based study Clin Infect Dis 19 1994 884 890
58. M.S. Niederman J.B. Bass Jr G.D. Campbell Jr Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy Am Rev Respir Dis 148 1993 1418 1426
59. Niederman M, Traub S, Ellison WT, et al: A double blind, randomized, multicenter, global study in trovafloxacin with ceftriaxone + erythromycin [Abstract LM-72]. 37th ICAAC, Toronto, Ontario, September 28-October 1, 1997.
60. K.M. Olsen G.S. San Pedro L.P. Gann Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses Antimicrob Agents Chemother 40 1996 2582 2585
61. J. Pachon M.D. Prados F. Capote Severe community-acquired pneumonia: Etiology, prognosis and treatment Am Rev Respir Dis 142 1990 369 373
62. R. Pallares J. Linares M. Vadillo Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain N Engl J Med 333 1995 474 480
63. J.E. Pennington Penetration of antibiotics into respiratory secretions Rev Infect Dis 3 1981 67 73
64. S.L. Phillips J. Branaman-Phillips The use of intramuscular cefoperazone versus intramuscular ceftriaxone in patients with nursing home-acquired pneumonia J Am Geriatr Soc 41 1993 1071
65. J.F. Plouffe R.F. Breiman Facklam R.R. Franklin County Pneumonia Study group Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention JAMA 275 1996 194
66. G. Rahav Y. Toledano D. Engelhard Invasive pneumococcal infections: A comparison between adults and children Medicine (Baltimore) 76 1997 295 303
67. K.A. Rodvold M.H. Gotfried L.H. Danziger Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers Antimicrob Agents Chemother 41 1997 1399 1402
68. O.D. Rotstein T.L. Pruett R.L. Simmons Mechanisms of microbial synergy in polymicrobial surgical infections Rev Infect Dis 7 1985 151 170
69. Saito A, Soejima R: The first comparative study with levofloxacin: A double-blind comparative study of gatifloxacin, a new quinolone, and levofloxacin in pneumonia [Abstract L-101]. Abstracts of the 38th ICAAC, San Diego, September 24-27, 1998.
70. D.A. Schiappa M.K. Hayden M.G. Matusek Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: A case-control and molecular epidemiologic investigation J Infect Dis 174 1996 529 536
71. P. Stapleton P.J. Wu A. King Incidence and mechanism of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother 39 1995 2478 2483
72. C. Thornsberry Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics against clinically important bacteria Am J Med 79 2A 1985 14
73. C. Thornsberry P. Ogilvie J.B. Kahn Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae , and Moraxella catarrhalis in the United States in 1996–1997 respiratory season Diagn Microbiol Infect Dis 29 1997 249 257
74. A. Torres R. Aznar J.M. Gatell Incidence, risk and prognosis factors of nosocomial pneumonia in mechanically ventilated patients Am Rev Respir Dis 142 1990 523 528
75. M.A. Visalli M.R. Jacobs P.C. Appelbaum Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared to susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin Antimicrob Agents Chemother 41 1997 1867 1870
76. R. Wise N. Brenwald M. Gill Streptococcus pneumoniae resistance to fluoroquinolones [letter] Lancet 348 1996 1660